Qingzhi Liu, Jinxi Wang, Jinping Liu, Likun Zhang, Ludovic Bourre, Jessie J.J. Wang
Acute myeloid leukemia (AML) is the most common acute type of leukemia in adults characterized by chromosomal abnormalities and gene mutations. While inhibitors have shown promise the emergence of drug resistance poses a significant challenge.
In this study, a panel of AML PDX models with multiple gene alterations was established to support the development of new therapies.
The results of this study showed the establishment of a panel of AML PDX models, including different subtypes and genomic features reflecting the clinic. Those models will support the preclinical evaluation of new treatments or combination modalities as well as a better understanding of drug resistance mechanisms.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-04-11
2024-03-28
landing_page
AACR 2024